Evidence map›Paper›PMID 34025837›Full record

ArticleArchives of medical science : AMS2021

High prevalence of anti-HEV antibodies among patients with immunosuppression and hepatic disorders in eastern Poland.

Anna Parfieniuk-Kowerda, Jerzy Jaroszewicz, Tadeusz W Łapiński, Mariusz Łucejko, Magdalena Maciaszek, Magdalena Świderska, Anna Grzeszczuk, Beata Naumnik, Mirosław Rowiński, Robert Flisiak

Open access · goldAbstract read
In one paragraph

Article in Archives of medical science : AMS, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.1field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Anna Parfieniuk-KowerdaDepartment of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland.
Jerzy JaroszewiczDepartment of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland.
Tadeusz W ŁapińskiDepartment of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland.
Mariusz ŁucejkoDepartment of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland.
Magdalena MaciaszekDepartment of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland.
Magdalena ŚwiderskaDepartment of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland.
Anna GrzeszczukDepartment of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland.
Beata NaumnikDepartment of Nephrology with Dialysis Unit, Medical University of Bialystok, Bialystok, Poland.
Mirosław RowińskiDepartment of Nephrology with Dialysis Unit, Medical University of Bialystok, Bialystok, Poland.
Robert FlisiakDepartment of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland.
Medical University of Białystok · PLMedical University of Silesia · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe incidence of hepatitis E virus (HEV) infections in Poland is largely unknown. This study aimed to describe seroprevalence of markers of HEV infection among patients with immunodeficiency of diverse etiology and patients with advanced chronic liver diseases. MATERIAL AND

methodsFour hundred fifty patients were enrolled; among them, 180 persons were solid organ transplant recipients, 90 patients were HIV-infected and 180 persons had confirmed liver cirrhosis of different etiology. Serum anti-HEV-IgG, IgM antibodies and HEV-antigen were detected by ELISA (Wantai, China).

resultsIn the group of transplant recipients, serum anti-HEV-IgG antibodies were detected in 40.6%, IgM in 1.1% and HEV-Ag in 2.8% of subjects. In the HIV-infected population 37.7% had anti-HEV-IgG, 1.1% had anti-HEV-IgM and none had HEV-Ag. Among patients with advanced chronic liver diseases the highest prevalence of anti-HEV-IgG was recorded in alcohol-related liver cirrhosis (52.1%) (

conclusionsIn this large cohort a high seroprevalence of anti-HEV-IgG was detected in comparison to other European countries, with the highest rates in patients with alcoholic liver disease and in transplant recipients.

Indexed as

epidemiologic data collectionhepatitis Ehepatitis E virusHIV infectionsliver diseases

Identifiers

PMID34025837
PMCPMC8130492
OpenAlexW2905459772

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.